Skip to content
My WebMD Sign In, Sign Up

Ovarian Cancer Health Center

Font Size

Ovarian Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Overview

Note: Separate PDQ summaries on Ovarian Cancer Prevention; Ovarian Epithelial Cancer Treatment; Ovarian Germ Cell Tumor Treatment; and Ovarian Low Malignant Potential Tumor Treatment are also available.

Evidence of Benefit or Lack of Benefit Associated with Screening

Recommended Related to Ovarian Cancer

Stage III and Stage IV Ovarian Epithelial Cancer Treatment

Treatment options for patients with all stages of ovarian epithelial cancer have consisted of surgery followed by chemotherapy. Surgery Patients diagnosed with stage III and stage IV disease are treated with surgery and chemotherapy; however, the outcome is generally less favorable for patients with stage IV disease. The role of surgery for patients with stage IV disease is unclear, but in most instances, the bulk of the disease is intra-abdominal, and surgical procedures similar to those...

Read the Stage III and Stage IV Ovarian Epithelial Cancer Treatment article > >

Single-threshold cancer antigen 125 (CA-125) levels and transvaginal ultrasound (TVU)

There is solid evidence to indicate that routine screening for ovarian cancer with the serum marker CA-125 and TVU does not result in a decrease in mortality from ovarian cancer.

Magnitude of Effect: No reduction in mortality

  • Study Design: Evidence obtained from one randomized controlled trial.
  • Internal Validity: Good.
  • Consistency: One trial has evaluated the impact on mortality from ovarian cancer.
  • External Validity: Good.

Statement of Harms

Based on solid evidence, routine screening for ovarian cancer results in false-positive test results among 9.6% of those screened; of those with false-positive results who had surgery, the complication rate was 20.6 cases per 100 surgical procedures. There were higher oophorectomy rates among screened women (85.7 per 10,000 person-years) than among usual care women (64.2 per 10,000 person-years). Minor complications with screening such as fainting and bruising occurred at a rate of 58.3 cases per 10,000 women screened with CA-125 and 3.3 cases per 10,000 women screened with TVS. There were more deaths from ovarian cancer in the screened group than in the usual care group, but the difference was not statistically significant.

Magnitude of Effect:

  • False-positive rate: 9.6%.
  • Minor complications with screening: 58.3 cases per 10,000 women screened with CA-125 and 3.3 cases per 10,000 women screened with TVS.
  • Proportion of women with false-positive results who had surgery: 32.9%.
  • Surgery complication rate: 20.6 cases per 100 surgical procedures.
  • Oophorectomy rates among screened women compared with usual care women: 85.7 versus 64.2 per 10,000 person-years.
  • Study Design: Evidence obtained from one randomized controlled trial.
  • Internal Validity: Good.
  • Consistency: Not applicable (N/A).
  • External Validity: Good.
1

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

what is your cancer risk
HEALTH CHECK
ovarian cancer overview slideshow
SLIDESHOW
 
cancer fighting foods
SLIDESHOW
15 Cancer Symptoms Women Ignore
FEATURE
 
Integrative Medicine Cancer Quiz
QUIZ
Lifestyle Tips for Depression Slideshow
SLIDESHOW
 
Screening Tests for Women
Slideshow
Graphic of ovaries within reproductive system
VIDEO
 
Ovarian Cancer Marker
VIDEO
Pets Improve Your Health
SLIDESHOW
 
Vitamin D
SLIDESHOW
Healthy meal with salmon
Article